Bausch + Lomb announced that it has begun distributing Vyzulta (latanoprostene bunod ophthalmic solution) .024% to US wholesale pharmaceutical distributors. Vyzulta will be available to patients across the United States through their local pharmacies within the next few days.
Vyzulta, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
"We're excited that Vyzulta is now available as a treatment option for people suffering from glaucoma," Joseph C. Papa, chairman and CEO of Valeant, the parent company of Bausch + Lomb, said in a company news release. "We remain committed to developing new innovative eye health medicines that can help address current and emerging unmet medical needs, particularly as the global population continues to advance in age."